Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott's Similac Recall Triggers Overflow Demand For Answers

This article was originally published in The Tan Sheet

Executive Summary

Consumer response to Abbott Laboratories' recall of powder Similac and other infant formula products initially exceeded the firm's capabilities to handle telephone calls and support online traffic to its websites
Advertisement

Related Content

Abbott Nutritionals Rise In Stature With Departure Of Branded Rx
Abbott Nutritionals Rise In Stature With Departure Of Branded Rx
Perrigo To Launch Private Label Mucinex, Prevacid, With An Eye On Lipitor
Abbott Says Nutritionals Can Succeed Without M&A Activity
Schumer Bill Would Prohibit Sale Of Recalled Products
Mead Johnson Labeling On Enfamil Pouches Draws Warning
Abbott Aims To Get Nutritionals Back On Track In Wake Of Similac Recall
Sales & Earnings In Brief
Sales & Earnings In Brief
Perrigo Grows Into Adjacent Infant Formula Category With PBM Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS104527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel